SSUR — StatSure Diagnostic Systems Share Price
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -60.14% |
Financial Summary
Year End 31st Dec | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008E | 2009E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.75 | 1.4 | 0.76 | 0.9 | 0.97 | n/a | n/a | 19.69% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
StatSure Diagnostic Systems, Inc. is engaged in marketing its Point-of-Care (POC) diagnostic test for the detection of HIV 1/ 2. The Company’s StatSure Diagnostic Systems, Inc.’s SURE CHECK HIV 1/ 2 and Clearview Complete HIV 1/ 2 tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2. The Company’s HIV 1/ 2 diagnostic test is manufactured in the United States by Chembio Diagnostics is sold in the United States to clinics, hospitals and physicians by Alere under the brand name Complete HIV 1/ 2. Since the Company has introduced HIV rapid test product, its annual sales have shown very rapid growth. The Company’s Barrel Test format which is easy to use, needs only 2.5ml of blood (a fingerprick) and is designed specifically for consumers will become the consumer test of choice.
Directors
- Last Annual
- December 31st, 2007
- Last Interim
- June 30th, 2008
- Incorporated
- January 9th, 1992
- Public Since
- June 21st, 2001
- No. of Shareholders
- 3,000
- No. of Employees
- 4
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 3,965,109.6

- Address
- 1881 Worcester Rd. No. 200, FRAMINGHAM, 01701
- Web
- http://www.statsurediagnostics.com/
- Phone
- +1 5088722625
- Auditors
- Lazar Levine & Felix LLP
Similar to SSUR
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 22:27 UTC, shares in StatSure Diagnostic Systems are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in StatSure Diagnostic Systems last closed at $0.00 and the price had moved by -98.62% over the past 365 days. In terms of relative price strength the StatSure Diagnostic Systems share price has underperformed the S&P500 Index by -98.97% over the past year.
There is no consensus recommendation for this security.
Find out moreStatSure Diagnostic Systems does not currently pay a dividend.
StatSure Diagnostic Systems does not currently pay a dividend.
StatSure Diagnostic Systems does not currently pay a dividend.
To buy shares in StatSure Diagnostic Systems you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in StatSure Diagnostic Systems had a market capitalisation of .
Here are the trading details for StatSure Diagnostic Systems:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SSUR
Based on an overall assessment of its quality, value and momentum StatSure Diagnostic Systems is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like StatSure Diagnostic Systems. Over the past six months, its share price has underperformed the S&P500 Index by -9.08%.
As of the last closing price of $0.00, shares in StatSure Diagnostic Systems were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The StatSure Diagnostic Systems PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
StatSure Diagnostic Systems' management team is headed by:
- Leo Ehrlich - PRE
- Moshe Bodner - CEO
- Joseph Levi - DRC